The Genomic Landscape and Its Clinical Implications in Hepatocellular Carcinoma
- Author:
Sun Young YIM
1
;
Ju Seog LEE
Author Information
- Publication Type:Review
- Keywords: Advanced hepatocellular carcinoma; Sorafenib; Adverse event; Pancreatic pseudocyst; Pancreatitis
- MeSH: Biomarkers; Carcinoma, Hepatocellular; Extracellular Matrix; Humans; Immunotherapy; Pancreatic Pseudocyst; Pancreatitis; Patient Care; Prognosis; Stromal Cells; Tumor Microenvironment
- From:Journal of Liver Cancer 2019;19(2):97-107
- CountryRepublic of Korea
- Language:English
- Abstract: The pathogenesis of hepatocellular carcinoma (HCC) is a complex process. During the last decade, advances in genomic technologies enabled delineation of the genomic landscape of HCC, resulting in the identification of the common underlying molecular alterations. The tumor microenvironment, regulated by inflammatory cells, including cancer cells, stromal tissues, and the surrounding extracellular matrix, has been extensively studied using molecular data. The integration of molecular, immunological, histopathological, and clinical findings has provided clues to uncover predictive biomarkers to enhance responses to novel therapies. Herein, we provide an overview of the current HCC genomic landscape, previously identified gene signatures that are used routinely to predict prognosis, and an immune-specific class of HCC. Since biomarker-driven treatment is still an unmet need in HCC management, translation of these discoveries into clinical practice will lead to personalized therapies and improve patient care, especially in the era of targeted and immunotherapies.
